**API and Formulations Platform Expands Operations**
SEKHMET PHARMAVENTURES, a conglomerate of Optimus and Drugs Optimus, announced its expanded operations at CPHI & PMEC India 2024. The company produces over 150 APIs, formulations, and offers CDMO (contract development and management) services.
With FDA, PMDA, and European GMP-approved assets, SEKHMET PHARMAVENTURES has a global reach. Its 150-member R&D team supports the development of complex chemistries, targeting both regulated and less regulated markets.Generated by Gemini
